The U.S. housing market started building up strength since the beginning of 2019, after a torrid second half of 2018. Declining mortgage rates and moderate home prices are likely to bring about a busy spring selling season for the industry.
Per mortgage finance company Freddie Mac’s Primary Mortgage Survey, the average U.S. 30-year fixed-rate mortgage slipped to the lowest level in a year to 4.28% for the week ended Mar 21 from 4.31% recorded a week ago. The said figure was also lower than the year-ago 4.45%.
The 15-year fixed-rate mortgage averaged 3.71%, down five basis points from 3.76% in the week earlier, while the five-year adjustable-rate mortgage was nearly flat at 3.84%. The decline is a welcome sign for potential buyers, who have been suffering affordability issues owing to rising rates and home prices.
Meanwhile, shares of notable homebuilding companies like Meritage Homes Corporation MTH, Beazer Homes USA, Inc. BZH, KB Home KBH, D.R. Horton, Inc. DHI and Lennar Corporation LEN rose 3.4%, 3%, 2.7%, 3.4% and 2.9%, respectively, on Mar 21.
Mortgage Applications Rise for 3rd Straight Week
According to the Mortgage Bankers Association's (MBA) Weekly Mortgage Applications Survey, mortgage applications for new home purchases increased 1.6% from the prior week on a seasonally adjusted basis, for the week ended Mar 15. Moreover, volumes are 1.8% higher than the year-ago level.
The rise mainly came from rate-sensitive refinance volume. Refinance applications rose 4% in the week and were 3.5% higher than a year ago.
Strengthening Housing Fundamentals
Strong confidence was noticed among homebuilders in the months of January and February for newly-built single-family homes, while the same remained stable in March, per the National Association of Home Builders/Wells Fargo sentiment index.
Further, total housing starts increased 18.6% in January from a month ago, per the U.S. Housing and Urban Development and Commerce Department. Additionally, low unemployment, solid job growth, wage gains and favorable demographics are likely to drive demand for homes in the upcoming season as well.
4 Must-Buy Housing Stocks
Adding some housing stocks to your portfolio looks like a smart move at this point as there are plenty of reasons to be optimistic about the sector over the short and long term. However, picking winning stocks may be difficult.
With the help of the Zacks Stock Screener, we have zeroed in on four stocks that have a Zacks Rank #1 (Strong Buy) or 2 (Buy) and a solid VGM Score. A top Zacks Rank indicates that these stocks have been witnessing positive estimate revisions, which generally translates into rapid price appreciation. You can see the complete list of today’s Zacks #1 Rank stocks here.
Our VGM Score identifies stocks that have the most attractive value, growth and momentum characteristics. In fact, our research shows that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 or 2, make a solid investment choice.
RH RH, a home furnishings retailer, currently flaunts a Zacks Rank #1. The stock has an expected earnings growth rate of 18.1% for fiscal 2019. Moreover, the company currently flaunts a VGM Score of A.
Loma Negra Compania Industrial Argentina Sociedad Anonima LOMA, which manufactures and markets cement and its by-products, currently carries a Zacks Rank #2. The Zacks Consensus Estimate for earnings calls for growth of 119.5% in 2019. Moreover, the company currently flaunts a VGM Score of A.
Forterra, Inc. FRTA, which is a manufacturer of various building products, currently carries a Zacks Rank #2. The Zacks Consensus Estimate for 2019 earnings calls for growth of 54.6% year over year. Moreover, the company currently has a VGM Score of B.
Armstrong World Industries, Inc. AWI, which designs and manufactures floors, ceilings and cabinets, currently carries a Zacks Rank #2. The Zacks Consensus Estimate for 2019 earnings are expected to grow 21.9% year over year. Moreover, the company currently flaunts a VGM Score of B.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Armstrong World Industries, Inc. (AWI) : Free Stock Analysis Report
FORTERRA INC (FRTA) : Free Stock Analysis Report
D.R. Horton, Inc. (DHI) : Free Stock Analysis Report
KB Home (KBH) : Free Stock Analysis Report
Lennar Corporation (LEN) : Free Stock Analysis Report
Beazer Homes USA, Inc. (BZH) : Free Stock Analysis Report
Meritage Corporation (MTH) : Free Stock Analysis Report
Restoration Hardware Holdings Inc. (RH) : Free Stock Analysis Report
Loma Negra Compania Industrial Argentina S.A. Sponsored ADR (LOMA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research